Heron Therapeutics (HRTX) Market Capitalization (2011 - 2026)

Heron Therapeutics (HRTX) has reported Market Capitalization for 16 consecutive years, with $81.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 74.27% year-over-year to $81.6 million; the trailing twelve-month figure through Jun 2026 stood at $81.6 million (down 74.27% YoY), and the FY2025 full-year result was $244.8 million, up 5.18% from the prior year.
• Market Capitalization declined to $81.6 million in Q2 2026 per HRTX's latest filing, from $151.4 million in the prior quarter.
• Across five years, Market Capitalization topped out at $586.2 million in Q1 2022 and bottomed at $81.6 million in Q2 2026.
• Historically, Market Capitalization has averaged $292.9 million across 5 years, with a median of $270.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Market Capitalization plunged 81.9% in 2022, then jumped 225.11% in 2024.
• Over 5 years, Market Capitalization stood at $297.9 million in 2022, then declined by 14.23% to $255.5 million in 2023, then retreated by 8.9% to $232.8 million in 2024, then grew by 5.18% to $244.8 million in 2025, then tumbled by 66.65% to $81.6 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $81.6 million, $151.4 million, and $244.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.